Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia (PALG-AML2012)

February 25, 2014 updated by: dr hab. n. med. Agnieszka Wierzbowska

Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells

In view of the diversity of the biology of acute myeloid leukemia (AML) therapy in individual patients must be individualized. One of the tools for this is molecular-cytogenetic stratification. It divides patients into five categories (prognostic groups): Favorable, Intermediate-1, Intermediate-2, Adverse and Very adverse risk. After remission proceedings are tailored depending on prognostic determined groups.

Research of PALG group in the application in the second line regimen CLAG and CLAG-M proved high effectiveness of this treatment with low toxicity. Considering experience of PALG groups, it seems that the use of the schema CLAG early as the second induction therapy is a viable treatment option.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Patients with AML with one of 5 prognostic categories based on modified cytogenetic-molecular stratification (European Leukemia Net Prognostic System - ENL)

Favorable risk

t(8;21)(q22;q22); RUNX1-RUNX1T1 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated NPM1 without FLT3-ITD (NK) Mutated CEBPA (NK)

Intermediate I risk

Mutated NPM1 with FLT3-ITD (NK) Wild-type NPM1 and FLT3-ITD (NK) Wild-type NPM1 without FLT3-ITD (NK)

Intermediate II risk

t(9;11)(p22;q22); MLLT3-MLL cytogenic abnormalities other than favorable or adverse

Adverse risk

Inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN-EVI1

Very adverse risk monosomal karyotype (MK): -5 or del(5q); -7; abnl(17p); complex karyotype

Goals:

  • Evaluation of the impact of therapy tailored to the risk factors on outcome of AML patients aged ≤ 60.
  • Evaluation of the possibility to improve the results of induction therapy through the use of early 2nd induction in patients with persistent leukemic infiltration of the bone marrow at the 14th day,
  • Evaluation of the impact of the minimal residual disease (MRD) presence assessed by Immunophenotyping method, on the results of treatment of AML patients aged ≤ 60,
  • Assessing the significance of monitoring the number of leukemic stem cells (LSC) in bone marrow and peripheral blood and their influence on clinical course and outcome of AML treatment,
  • Assessment of the LSC determination usefulness in MRD monitoring in patients with AML,
  • Evaluation of the prognostic significance of the expression of CXCR-4 on the surface of leukemic cells and their impact on the clinical course and outcome of AML - trying to select a group of patients who potentially would benefit from the use of chemosensitization with plerixafor,
  • Evaluation of autologous HSCT effectiveness in consolidation therapy in AML patients from 3 following cytogenetic-molecular risk groups: Favorable, Intermediate I, Intermediate II,
  • Comparison of the overall survive (OS) and leukemia-free survival after autologous and allogeneic HSCT in AML patients from Intermediate I and Intermediate II cytogenetic-molecular risk groups (biological randomization donor vs. donor).

Study Type

Interventional

Enrollment (Anticipated)

400

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Poland
      • Lodz, Poland, 93-510
        • Recruiting
        • Copernicus Memorial Hospital
        • Principal Investigator:
          • Agnieszka Wierzbowska, Dr hab. n. med.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 58 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adult acute myeloid leukemia
  • Age: ≥18 and ≤ 60
  • Clinical condition of the patient allows to carry out induction therapy: ECOG performance status: ≤ 2 and the Hematopoietic Cell Transplant-Co-morbidity Index (HCT-I): ≤3
  • Informed consent to participate in the study (ICF signed)
  • The second early induction start criteria is in addition to the listed above, the percentage of the blasts on the level >10% on 7th day.

Exclusion Criteria:

  • No informed consent for participation in the study, mental illness, which don't allow to obtain informed consent and conduct the treatment according to the protocol
  • Pregnancy
  • HIV infection
  • Active cancer
  • Active hepatitis virus infection

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Induction, DAC

The first stage of treatment.

First DAC induction cycle is common to all patients (regardless of risk group). After completion of induction I occurs early assessment of bone marrow on the +14 day after the start of treatment (+7 day after completion of chemotherapy).
Drug: DAC
  • DNR 60 mg/m2 0,5h infusion iv on 1-3 days
  • 2-CdA 5 mg/m2 2h. infusion iv on 1-5 days
  • Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days
Other Names:
  • - Cladribine
  • - Cytosine arabinoside [Ara-C]
  • - Daunorubicin
Other: II early induction, CLAG

Patients with blasts in the bone marrow in D14> 10% receive early second induction (CLAG) which start form +16 day.

Patients with blasts in the bone marrow in D14 ≤ 10% do not receive early second induction and are qualified to assess the response times on +28 day or after full morphology recovery (if it occurs before the +28 day
Drug: CLAG
  • G-CSF 30MU sc, on 0-5 days
  • Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days
  • Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days
  • Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day
Other Names:
  • - Cladribine
  • - Granulocyte-colony stimulating factor [G-CSF]
  • - Mitoxantrone
  • - Cytosine arabinoside [Ara C]
Other: Consolidation, I HAM cycle

I induction cycle starts after complete remission (CR).

- After I consolidation, patients from Intermediate I an Intermediate II group (ELN prognostic system):

If compatible donor is present - allogeneic HSCT qualification after I or II consolidation. If compatible donor for allogeneic HSCT is not present - attempt to CD34+ mobilization for autologous SCT after II consolidation

- After I consolidation, patients from Adverse risk group (ELN prognostic system):

If compatible donor is present - immediate qualification for allogeneic HSCT.

- Finding a donor should be initiated in all patients, at the latest after the end of I induction. In the first place, it should be checked whether the patient has a donor family, if not - searching start for an unrelated donor. For patients with no compatible donor for allogeneic HSCT - need to start searching for an alternative donor
Drug: Consolidation, I HAM cycle
  • Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days
  • Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days
Other Names:
  • - Cytosine arabinoside [Ara-C]
  • - Mitoxantrone
Other: II Consolidation HiDAraC

Patients from all 5 risk group receive second after first consolidation [Ara-C] Patient from Very adverse risk receive Ara-C + CLA (Cladribine). If it is needed - more intensive consolidation treatment with 2-Cda.

Patients form Very adverse risk receive Maintenance treatment:

Decitabine 20 mg/m2 60 min infusion iv (Intravenous injection) for 5 days every 6 weeks.

Patients from Favorable, - Intermediate I an Intermediate II risk groups: CD34+ mobilization (HSCT qualification).
Drug: II Consolidation HiDAraC
• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
Other Names:
  • - Cladribine
  • - Cytosine arabinoside [Ara-C]
Other: Consolidation, III HiDAraC cycle

Patients from Favorable, Intermediate I an Intermediate II risk groups receive III consolidation or autologous HSCT (depends on results of mobilization).

Patients from Adverse risk receive III Consolidation HiDAraC + Cladribina (CLA) If no CR: CLAG-M reinduction therapy and after CR - treatment according to protocol.
Drug: Consolidation, III HiDAraC cycle
  • Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days
  • 2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C
Other Names:
  • - Cytosine arabinoside [Ara-C]
  • - 2-CdA [Cladribine, 2-Chlorodeoxyadenosine]

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complete remission after induction
Time Frame: 28 days

Outcome measure after induction:

At +28 day after treatment or after full morphology recovery (if it occurs before the +28 day)

Complete remission, according to Cheson's CR criteria:

  • Lack of extramedullary infiltration,
  • Platelet count> 100 G / L,
  • Neutrophil count> 1.0 G / L,
  • Lack of blast cells in the blood,
  • Bone marrow blasts <5% in the cytomorphology.

After induction treatment, patients are qualified for one of the pro-remission treatment options, which is associated with cytogenetic-molecular risk groups, according to the modification of the molecular ELN / MDACC.

Therapeutic decisions are being made according to cytogenetic-molecular stratification: Favorable, Intermediate-1, Intermediate-2, Adverse and Very adverse risk.
28 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

dr hab. n. med. Agnieszka Wierzbowska

Collaborators

Copernicus Memorial Hospital
Polish Adult Leukemia Group

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2014

Primary Completion (Anticipated)

February 1, 2018

Study Completion (Anticipated)

February 1, 2018

Study Registration Dates

First Submitted

February 24, 2014

First Submitted That Met QC Criteria

February 25, 2014

First Posted (Estimate)

February 27, 2014

Study Record Updates

Last Update Posted (Estimate)

February 27, 2014

Last Update Submitted That Met QC Criteria

February 25, 2014

Last Verified

February 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PALG-AML2012

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Myeloid Leukemia

Clinical Trials on DAC

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe